Loading…
Loading…
688176.SS does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for 688176.SS and 80,000+ other tickers.
See exactly how 688176.SS's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 688176.SS and 80,000+ other tickers.
Established in 2010 and headquartered in Shanghai, China, Jiangsu Yahong Meditech Co., Ltd. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutic drugs. Its primary focus lies in medicines targeting genitourinary system cancers, though its pipeline extends to a variety of other diseases, serving both domestic Chinese and international markets. The company's clinical-stage pipeline features several key candidates. Notably, two compounds, APL-1202 (an anti-tumor drug) and APL-1706 (an agent drug), are both undergoing Phase III…
/PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that
/PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that
/PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that